Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

230 Press Releases
DateTitleCompany
28 Apr 14 Positive CHMP opinion for Pradaxa® in treatment of deep vein thrombosis and pulmonary embolism and prevention of repeat blood clots Boehringer Ingelheim,
Published by
Business Wire
08 Apr 14 FDA approves Pradaxa® for treatment and reduction in risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE) Boehringer Ingelheim,
Published by
Business Wire
06 Mar 14 Pradaxa® (dabigatran etexilate) now approved in over 100 countries for stroke prevention in atrial fibrillation Boehringer Ingelheim,
Published by
Business Wire
01 Mar 14 ASTHMA: New Phase III data show tiotropium* Respimat® effective across asthma severities Boehringer Ingelheim,
Published by
Business Wire
29 Jan 14 Pcovery expands investor base with corporate investor Boehringer Ingelheim Venture Fund Boehringer Ingelheim
17 Dec 13 New data on safety and efficacy of Pradaxa® in treatment of acute deep vein thrombosis and pulmonary embolism Boehringer Ingelheim,
Published by
Business Wire
16 Dec 13 Hepatitis C: Phase III data show Boehringer Ingelheim’s faldaprevir* is effective even in patients with common drug-resistant viral variant Boehringer Ingelheim,
Published by
Business Wire
09 Dec 13 Boehringer Ingelheim Scores Perfect 100 in Human Rights Campaign’s Corporate Equality Index Boehringer Ingelheim,
Published by
Business Wire
19 Nov 13 Boehringer Ingelheim planning two new Global Clinical Trials for Pradaxa® (dabigatran etexilate) in expanded patient populations Boehringer Ingelheim,
Published by
Business Wire
19 Nov 13 New long-term treatment data confirms consistent benefit and safety profile of Pradaxa® beyond 6 years Boehringer Ingelheim,
Published by
Business Wire
18 Nov 13 First human data show promise of Boehringer Ingelheim’s specific antidote for immediate, complete and sustained reversal of Pradaxa®-induced anticoagulation Boehringer Ingelheim
18 Nov 13 First human data show promise of Boehringer Ingelheim’s specific antidote for immediate, complete and sustained reversal of Pradaxa®-induced anticoagulation Boehringer Ingelheim,
Published by
Business Wire
07 Nov 13 New data presented at AASD further demonstrate benefits of Trajenta® (linagliptin) with efficacy and safety in specific patient populations Boehringer Ingelheim,
Published by
Business Wire
28 Oct 13 New efficacy and safety data adds to evidence supporting treatment with afatinib* (GIOTRIF®) in Asian and non-Asian lung cancer patients Boehringer Ingelheim,
Published by
Business Wire
18 Oct 13 New once-daily Striverdi* (olodaterol) Respimat® gains approval in first EU countries Boehringer Ingelheim,
Published by
Business Wire
14 Oct 13 Boehringer Ingelheim submits nintedanib*, a novel oncology compound, for European approval Boehringer Ingelheim,
Published by
Business Wire
30 Sep 13 Nintedanib* extended survival beyond one year for advanced adenocarcinoma patients after prior first-line chemotherapy Boehringer Ingelheim,
Published by
Business Wire
27 Sep 13 New Irish online COPD resource at the click of a button Boehringer Ingelheim,
Published by
Porter Novelli
24 Apr 13 Boehringer Ingelheim consistently continues growth phase in financial year 2012 Boehringer Ingelheim
21 May 13 Phase III results: Once-daily tiotropium* effective in symptomatic asthma patients irrespective of their age, allergic status, smoking status and bronchodilator response Boehringer Ingelheim
11 Mar 13 American College of Cardiology and Boehringer Ingelheim collaborate to advance physician education with focus on China in 2013 Boehringer Ingelheim,
Published by
Business Wire
11 Mar 13 Pharmaco-invasive strategy including Metalyse® delivers comparable clinical outcomes to primary PCI for STEMI patients who could not undergo primary PCI within one hour from first medical contact Boehringer Ingelheim
09 Sep 13 Landmark TIOSPIR™ trial further reinforces safety and efficacy profile of Spiriva® Respimat® in the treatment of COPD Boehringer Ingelheim
26 Mar 13 FDA perspective published in the New England Journal of Medicine reinforces safety of Pradaxa® (dabigatran etexilate) Boehringer Ingelheim,
Published by
Business Wire
26 Mar 13 Boehringer Ingelheim and Eli Lilly and Company announce acceptance of European marketing authorisation application for investigational Type 2 Diabetes treatment empagliflozin* Boehringer Ingelheim,
Published by
Business Wire
03 Jun 13 Superiority of afatinib* over comparator chemotherapy for patients with EGFR mutation-positive advanced lung cancer is reinforced by second Phase III study Boehringer Ingelheim,
Published by
Pharmiweb.com
23 Feb 13 Phase III results: tiotropium* Respimat® is effective in symptomatic asthma patients irrespective of their allergic status Boehringer Ingelheim,
Published by
Business Wire
19 Mar 13 Boehringer Ingelheim and Lilly initiate MARLINA™ clinical trial to evaluate use of Trajenta® (linagliptin) in patients with type 2 diabetes and albuminuria Boehringer Ingelheim,
Published by
Business Wire
03 Sep 13 Pradaxa® (dabigatran etexilate) drives Boehringer Ingelheim’s innovation promise in cardiovascular diseases Boehringer Ingelheim,
Published by
Business Wire
24 Jun 13 Application submitted to the EMA for use of dabigatran etexilate in treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE Boehringer Ingelheim
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.